

Next Generation Immunotherapy Discoveries

Organizers: Innate Pharma, Mount Sinai School of Medicine
Mount Sinai School of Medicine, New York - October 3, 2024

MORNING PROGRAM

- 9:30 am – 10:00 am *Opening coffee*
- 10:00 am – 10:15 am **Welcome:**
Hervé Brailly
Chairman of the Executive Board and Chief Executive Officer of Innate Pharma
Miriam Merad
Chair of the Department of Immunology and Immunotherapy of Mount Sinai
School of Medicine

Next generation immunotherapy discoveries applied to clinic

Chair: Joao Monteiro, Nature Medicine

- 10:15 am – 10:45 am Pierluigi Porcu, Thomas Jefferson University
“Novel therapies in T-cell malignancies: preclinical and clinical studies”
- 10:45 am – 11:15 am Eric Vivier, Innate Pharma; Centre d’Immunologie Marseille-Luminy
“Harnessing NK cells in therapies”
- 11:15 am – 11:30 am *Break*
- 11:30 am – 12:00 pm Lorenzo Falchi, Memorial Sloan Kettering Cancer Center
“NK engagers for the treatment of B-cell lymphoma: Preclinical development and clinical applications”
- 12:00 pm – 12:30 pm Katy Rezvani, MD Anderson Cancer Center
“NK cells: next generation cell therapies for cancer”
- 12:30 pm – 2:00 pm *Lunch Break*

AFTERNOON PROGRAM

Next generation immunotherapy discoveries

Chair: Amir Horowitz, Mount Sinai School of Medicine

- 2:00 pm – 2:30 pm Dimitri Skokos, Regeneron Pharmaceuticals, Inc.
“Tumor-targeted costimulation via CD28 bispecific antibodies: Turning immunotherapy “cold” tumors “hot””
- 2:30 pm – 3:00 pm Miriam Merad, Mount Sinai School of Medicine
“Targeting pathogenic myelopoiesis in cancer”
- 3:00 pm – 3:30 pm Antoni Ribas, University of California
“Effects of MHC class I expression in PD-1 blockade therapy”
- 3:30 pm – 4:00 pm *Break*
- 4:00 pm – 4:30 pm Tom Marron, Mount Sinai School of Medicine
“Therapeutic targeting of Type-2 immunity in cancer”
- 4:30 pm – 5:00 pm Diane Mathis, Harvard Medical School
“Tissue-Treg control of local IFN γ responses, a commonality”